IMTX
Immatics NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.55B
P/E Ratio
—
EPS
$-1.88
Beta
1.34
52W High
$12.41
52W Low
$3.94
50-Day MA
$10.24
200-Day MA
$8.99
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immatics NV
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
Fundamentals
| Revenue (TTM) | $48.27M |
| Gross Profit (TTM) | $-135.57M |
| EBITDA | $-172.88M |
| Operating Margin | -196.80% |
| Return on Equity | -37.10% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $0.39 |
| Book Value | $4.26 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 32.20 |
| EV/Revenue | 17.5 |
| EV/EBITDA | 7.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -64.90% |
| Shares Outstanding | $134.10M |
| Float | $67.27M |
| % Insiders | 17.92% |
| % Institutions | 76.42% |
Historical Volatility
HV 10-Day
20.98%
HV 20-Day
30.96%
HV 30-Day
37.37%
HV 60-Day
55.26%
HV Rank
0.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($18.75 target)
9
BuyData last updated: 4/29/2026